Dynavax Technologies Corp. reported a loss of $17.7 million for the quarter ended June 30, compared with a loss of $15.3 million in the same quarter a year ago.The Berkeley company (NASDAQ: DVAX) is testing and developing the drug Heplisav to prevent hepatitis B. Higher clinical trial costs added to its loss. It is also working on Tolamba, a ragweed allergy treatment.
